Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Idorsia Ltd
  6. Summary
    IDIA   CH0363463438

IDORSIA LTD

(IDIA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
11/22/2021 11/23/2021 11/24/2021 11/25/2021 11/26/2021 Date
16.69(c) 16.43(c) 16.16(c) 16.3(c) 16.3(c) Last
317 225 418 472 457 750 298 470 609 008 Volume
-1.53% -1.56% -1.64% +0.87% 0.00% Change
More quotes
Estimated financial data (e)
Sales 2021 37,8 M 40,9 M 40,9 M
Net income 2021 -606 M -656 M -656 M
Net Debt 2021 558 M 605 M 605 M
P/E ratio 2021 -4,42x
Yield 2021 -
Sales 2022 108 M 117 M 117 M
Net income 2022 -641 M -694 M -694 M
Net Debt 2022 785 M 851 M 851 M
P/E ratio 2022 -4,45x
Yield 2022 -
Capitalization 2 884 M 3 125 M 3 125 M
EV / Sales 2021 91,2x
EV / Sales 2022 34,1x
Nbr of Employees 650
Free-Float 65,6%
More Financials
Company
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan... 
More about the company
Ratings of Idorsia Ltd
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about IDORSIA LTD
11/01Idorsia to Proceed With Late-Stage Study of Lupus Disease Treatment
MT
11/01Idorsia to advance cenerimod into Phase 3 development for treatment of patients with sy..
AQ
11/01Idorsia Ltd to Advance Cenerimod into Phase 3 Development for Treatment of Patients wit..
CI
10/28Johnson & Johnson Unit To Partially Convert Loan To Idorsia
MT
10/27Johnson & Johnson partially converts its convertible loan
AQ
10/26Idorsia Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021
CI
10/26IDORSIA : Financial Report Nine-Month 2021
PU
10/26IDORSIA : Q3 Loss Widens As Operating Expenses Grow
MT
10/26IDORSIA : announces financial results for the third quarter 2021 – company progressi..
AQ
10/14ANALYST RECOMMENDATIONS : Asos, Avis Budget, Meritage Homes, Kansas City Southern, UPS...
10/11GLOBAL MARKETS LIVE : Facebook, Apple, KKR, Adler, Roche...
10/11IDORSIA : Fabry Disease Therapy Misses Primary Endpoint In Late-Stage Trial
MT
10/11IDORSIA : announces the results of MODIFY, a Phase 3 study of lucerastat in Fabry disease
PU
08/06Antares pharma reports second quarter 2021 financial and operating resultsewing
AQ
07/29IDORSIA : Application of Jean-Paul and Martine Clozel regarding the exemption from the off..
PU
More news
News in other languages on IDORSIA LTD
11/23Santhera revendique le succès d'un programme contre la maladie de Duchenne
11/18AKTIEN SCHWEIZ VORBÖRSE : SMI trotz Inflationssorgen auf Rekordniveau
11/03OPINIONES DE LOS ANALISTAS DEL DÍA : BMW ,BBVA, Roche, Hellofresh, chegg, Linde, ABB, Unde..
11/03Es el día de la Fed
11/03AVIS D'ANALYSTES DU JOUR : Orange, Unibail, Worldline, Roche, ABB, Under Armour ...
More news
Analyst Recommendations on IDORSIA LTD
More recommendations
Chart IDORSIA LTD
Duration : Period :
Idorsia Ltd Technical Analysis Chart | IDIA | CH0363463438 | MarketScreener
Technical analysis trends IDORSIA LTD
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Last Close Price 16,30 CHF
Average target price 27,07 CHF
Spread / Average Target 66,1%
EPS Revisions
Managers and Directors
Jean-Paul Clozel Chief Executive Officer & Director
AndrÚ C. Muller Chief Financial Officer & Executive Vice President
Mathieu Simon Chairman
Guy Braunstein Executive VP & Head-Global Clinical Development
Martine Clozel Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
IDORSIA LTD-36.13%3 125
GILEAD SCIENCES, INC.20.61%88 146
BIONTECH SE326.89%84 049
REGENERON PHARMACEUTICALS33.17%67 266
WUXI APPTEC CO., LTD.24.40%64 416
VERTEX PHARMACEUTICALS-22.32%46 678